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Preoperative Weight Loss With GLP-1 Receptor Agonist Treatment 
Predicts Greater Weight Loss Achieved by the Combination of Medical 
Weight Management And Bariatric Surgery In Patients With Type 2 
Diabetes: A Longitudinal Analysis  
Supplementary Appendix 
 
Supplementary Background 
Bariatric surgery is currently the most effective method to achieve long-term substantial sustainable 
weight loss in patients with obesity.1 The weight loss following bariatric surgery varies considerably 
amongst individuals with Laparoscopic Adjustable Gastric Banding (LAGB) resulting in 15-25% weight 
loss compared to Roux-en-Y Gastric Bypass (RYGB) and Laparoscopic Sleeve Gastrectomy (LSG) both 
resulting in 25-35% weight loss respectively over 10 years period.2–4 
We hypothesized that greater weight change achieved by GLP-1 RA before surgery predicts greater 
post-surgical weight loss and greater weight loss from the start of MWM to 12 months post-surgery. 
A secondary aim of our study was to assess the relationship between weight changes following 
preoperative GLP-1 RA treatment and surgically-induced weight changes at 12 months after bariatric 
surgery. 
Supplementary Methods 
Patient inclusion and exclusion criteria 
Patients with T2DM who underwent bariatric surgery were identified from the bariatric surgery 
database at our centre.  To be included in the analysis, patients had to be adults with T2DM, who 
underwent preoperative GLP-1RA treatment under the care of our centre and then underwent 
bariatric surgery between the years 2011 and 2014. Receiving GLP-1 RA was at the discretion of the 
treating physician.  
Only patients who attended at least 12 months post-bariatric surgery follow-up were included. Data 
regarding the preoperative treatment and the details of GLP-1 RA treatment were obtained from the 
patients’ electronic hospital records at our centre.  The titration, stopping or continuation of GLP-1 
RA treatment were made based on clinical grounds by the treating physicians. As per our clinic 
protocols, GLP-1 RA treatment was continued to the time of surgery when possible and stopped 
before surgery. GLP-1 RA treatment were only used after surgery for glycaemic control at the 
discretion of the treating physician. 
Clinical Setting 
Patients were referred to the Tier 3 MWM at our centre if they had a body mass index (BMI) ≥ 35 
kg/m2 with at least one obesity-related comorbidity or BMI ≥ 40 kg/m2 with or without 
comorbidities. The Tier 3 MWM provides input from bariatric physicians, specialist dieticians, a 
psychologist, and a specialist nurse. Patients generally spend 12-24 months in the Tier 3 services 
before being referred to the surgical team for the consideration of bariatric surgery.5 Whilst in the 
Tier 3 services, patients receive a combination of lifestyle and behavioural intervention delivered in 
group sessions and in 1-to-1 appointments. These interventions are coupled with pharmacotherapy 
where deemed appropriate at the discretion of the health care professionals at any time point 
during the MWM. All patients in our service received medical weight management regardless 
whether pharmacotherapy was used or not. 
Data Collected 
The following data were collected: Start and end dates of Tier 3 MWM; Start and end dates of GLP-1 
RA treatment; name of the GLP-1 RA; type of bariatric procedure; weight (kg) and BMI (kg/m2) at the 
start and end of MWM, the start and end of GLP-1 RA treatment, from the day of surgery and 12 
months post-bariatric surgery. These values were used to calculate the weight changes in kilograms 
and percentages as follows (Figure S1): 
• Total weight change (TWC) in Kg: weight measured at start of MWM – weight at 12 months 
post-bariatric surgery 
• Pre-GLP-1 RA weight change in Kg:  MWM Baseline weight – Weight at the start of GLP-1 RA 
treatment 
• Percentage weight change before GLP-1 RA treatment (%): Point 2/ MWM baseline weight 
GLP-1 RA induced weight change in Kg: Weight at the start of GLP-1 RA – weight at the end of GLP-1 
RA 
• Percentage GLP-1 RA induced weight change: weight calculated form point 4/ weight at the 
start of GLP-1 RA 
• Weight change induced by surgery in Kg: weight day of surgery – weight at 12 months post-
surgery 
• Percentage weight change induced by surgery: weight calculated from Point 6/ weight day of 
surgery 
• Proportion of total weight change attributed to weight change before GLP-1 RA treatment (%): 
point 2/ point 1 
• Proportion of total weight change attributed to GLP-1 RA treatment (%): weight calculated from 
point 4/ weight calculated from point 1 
• Proportion of total weight change attributed to surgery (%): weight change calculated from 
point 6/ weight change from point 1 
In this brief report and based on the methods of calculation detailed above, positive weight change 
values denoted weight loss, whilst negative values denoted weight gain. In this study, we defined a 
lack of weight loss (i.e. weight maintenance or weight gain) as weight loss < 3% of total body weight 
or weight gain as used in previous studies.6  
Ethical considerations 
The project was registered and approved as a clinical audit/health service evaluation at the 
department of diabetes and endocrinology at Birmingham Heartlands Hospital and carried out as 
part of a health service evaluation to assess weight loss predictors and outcomes of patients 
undergoing bariatric surgery at our centre. All data collected was part of routine care, and only 
anonymized data were used in this analysis.  
Statistical Analysis 
Data analysis was performed using SPSS Statistics 23 (IBM). Depending on data distribution, the data 
was presented as either frequencies, mean ± SD, or median ± IQR. Data distribution was assessed 
using the Shapiro-Wilko test. The relationship between continuous variables (such as weight 
changes) were assessed using either Pearson’s or Spearman’s test depending on data distribution. 
Differences between variables were performed using the Chi-square test in the case of categorical 
variables and the independent t-test or the Mann-Whitney U test in the case of continuous variables 
depending on data distribution. 
Predictors of post-operative weight change and TWC were assessed using multiple linear regression. 
Variables included in the regression models were based on their relevance biologically and 
epidemiologically to the outcome of interest. Assumptions of linear regression were examined and 
adhered to. 
Due to the different mechanisms of action between different types of bariatric surgery, the data 
analysis was performed in two subgroups: LAGB and RYGB/LSG. The RYGB and LSG were combined 
due to the limited sample size. A p<0.05 was considered statistically significant throughout the brief 
report. 
Supplementary Results 
Forty-five patients were included in this analysis (26 gastric band, 16 RYGB and 3 LSG). The study 
population was mostly composed of middle age women with grade III obesity (Table S1). Liraglutide 
once-daily was used in 35 patients, while 10 patients received Exenatide twice-daily.  Eight patients 
received GLP-1 RA treatment post-operatively to improve glycaemic control at the discretion of the 
treating physician. 
Weight changes during the study 
GLP-1 RA and bariatric surgery resulted in significant weight loss (Table S2). Overall, LAGB resulted in 
7.3 (2.9 to 9.9) % weight loss and RYGB/LSG resulted in 24.7 (19.5 to 25.9) % weight loss calculated 
from the day of surgery till 12 months post-bariatric surgery (Table S2).  Calculating the weight loss 
from the start of Tier 3 MWM showed that patients who had LAGB lost 13.8 (6.9 to 17.6) % and 
those who had RYGB/LSG lost 29.3 (23.1 to 34.3) %(Table S2). 
The relationships between pre- and post-operative weight changes 
There was no relationship between GLP-1 RA induced weight change and the weight change induced 
by bariatric surgery over 12 months, regardless of the type of the surgical procedure (Tables S3 and 
S4).  Comparing the weight changes at multiple timepoints before and after surgery in patients who 
lost ≥ 3%, 5% or 8% of their weight on GLP-1 RA treatment vs. those who lost <3%, 5% or 8% body 
weight respectively can be found in Table S4. There was no differences in % weight loss from day of 
surgery to 12 months post-surgery in patients who lost ≥ 3, 5 or 8% of their weight following GLP-1 
RA vs. those who lost < 3, 5 or 8% respectively regardless of the type of procedure. However, the % 
body weight loss between start of MWM and 12 months post-operatively was greater, albeit not 
statistically significant, in LAGB patients who lost ≥ 3% body weight following GLP-1 RA treatment 
and was significantly greater in patients who received LSG/RYGB who lost ≥ 8% body weight 
following GLP-1 RA treatment. 
Using multiple linear regression and after adjusting for % weight change from baseline to the start of 
GLP-1 RA, the % weight change induced by GLP-1 RA, baseline weight, gender, age and type of 
surgery (for the model: R= 0.761, R2= 0.580); % weight change from the day of surgery to 12 months 
post-operatively was predicted by having RYGB/LSG (B=0.168, p<0.001) and % weight change from 
baseline MWM to the start of GLP-1 RA (B= -0.587, p=0.03). Percentage weight change because of 
GLP-1 RA treatment did not predict 12 months post-operative weight loss (B= -0.15, p=0.5). These 
results suggest that having LSG/RYGB predicted greater weight loss after surgery. However, greater 
% weight loss before starting GLP-1 RA predicted lower % weight loss after bariatric surgery. 
Similarly, following adjustments for age, sex, surgical procedure, baseline weight (kg), weight change 
before starting GLP-1 RA (in Kg) and weight change after starting GLP-1 RA (Kg) (for the model: 
R=0.793, R2= 0.630); predictors of weight change from preoperative weight to 12 months post-
surgery weight in kg were: age (B=0.337, p=0.023), baseline weight (B=0.217, p=0.004) and weight 
change from baseline MWM to starting GLP-1 RA (B=-0.9, p<0.001).  Weight change due to GLP-1 RA 
treatment was not a predictor of the weight change post-operatively (B=-0.301, p=0.169). The 
results suggest that higher baseline weight (in kg) and older patients had greater weight loss (in kg) 
after surgery, while patients who lost more weight (in kg) before starting the GLP-1 RA treatment 
lost less weight (in kg) after surgery.  
Supplementary Discussion 
Evaluation of secondary aim and study 
Our secondary aim was to assess the relationship between weight loss achieved through 
preoperative GLP-1 RA treatment and weight loss 12 months after bariatric surgery. Our data have 
shown that the impact of GLP-1 RA treatment before bariatric surgery does not predict the weight 
loss achieved following bariatric surgery. There was no difference in post-bariatric surgery weight 
loss in those who lost weight following GLP-1 RA treatment and those who did not lose weight. 
While this might be understandable in patients undergoing LAGB, as the weight loss mechanism is 
not believed to be related to GLP-1, the findings are surprising in patients who underwent RYGB or 
LSG.  
Limitations and Strengths 
Our study has several limitations. Our sample size is small and the duration and timing of treatment 
of GLP-1 RA varied considerably amongst patients depending on the clinical care. Despite this, the 
correlation coefficients do not show any trend towards a positive association between weight loss 
following GLP-1 RA and weight loss following bariatric surgery. Another limitation is the possibility of 
confounding by indication. Most patients with T2DM in the MWM did not receive GLP-1 RA 
treatment and hence the indication for starting the GLP-1 RA treatment by the treating clinician 
might have confounded our findings. Our study was limited to patients with T2DM as GLP-1 RA was 
not licensed and was not available to treatment of obesity outside the context of T2DM. 
Our study also has its strengths: it is the first to examine the relationship between dynamic weight 
changes due to GLP-1 RA treatment and post-surgery weight loss and our patients received intensive 
life style intervention by an experienced team before and after bariatric surgery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Tables and Figures 
Table S1. Patient Demographics and baseline characteristics. Data presented as median (IQR) or percentages. MWM: 
Medical Weight Management Services; BMI: Body Mass Index; GLP-1 RA: Glucagon-like peptide -1 receptor agonist LAGB: 
Laparoscopic Adjustable Gastric Band; RYGB: Roux-en-Y Gastric Bypass; LSG: Laparoscopic Sleeve Gastrectomy. 
 Total Study 
Population 
LAGB RYGB/ LSG 
N 45 26 19 
Age at time of surgery 49 (45 to 60) 52.5 (45 to 60) 47 (45 to 58) 
Baseline Weight at MWM (kg) 136 (119.1 to 
132.4) 
137.7 (120.5 to 
155.2) 
125.7 (113.6 to 140.4) 
Baseline BMI at MWM (kg/m2) 46.2 (43.1 to 
53.9) 
48.3 (44.8 to 55.5) 44 (42.9 to 48.2) 
Women (%, N) 64.4%, N=29 65.4%, N=17 63.2%, N=12 
Length of GLP-1 RA treatment 
(days) 
454 (206.5 to 
644) 
416.5 (213.25 to 
643.5) 
455 (177 to 788) 
Time in MWM before 
initiating GLP-1 RA treatment 
(days) 
118 (11.5 to 320) 193.5 (74.25 to 392) 45 (0 to 195) 
 
Table S2.Summary of weight changes (in Kg and %) during the different stage of the study. Data presented as median (IQR).  
Negative values indicate weight gain. GLP-1 RA: Glucagon-like peptide-1 receptor agonist; MWM: Medical Weight 
Management Services; TWC: Total Weight Change; LAGB: Laparoscopic Adjustable Gastric Band; RYGB: Roux-en-Y Gastric 
Bypass; LSG: Laparoscopic Sleeve Gastrectomy. 
Weight Change Total study population 
Weight Change (Kg and 
%) 
LAGB 
Weight Change (Kg and 
%) 
RYGB/LSG 
Weight Change (Kg 
and %) 
Prior to GLP-1 RA treatment 1.1 (0 to 5.3) kg 
0.7 (0 to 3.6) % 
1.7 (-0.1 to 6.15) kg 
1.3 (-0.1 to 3.9) % 
0.4 (0 to 3.8) kg 
3.3 (0 to 3.5) % 
During GLP-1 RA treatment 6.1 (2.6 to 13.0) kg 
5.0 (1.9 to 7.7) % 
7.4 (1.6 to 11.4) kg 
5.7 (1.3 to 7.8) % 
5.8 (3.2 to 13.4) kg 
4.8 (2.1 to 7.8) % 
From day of surgery to 6 months 
Postoperative 
14.9 (10.1 to 22.5) kg 
12.4 (7.3 to 21.3) % 
11.5 (2.6 to 14.5) kg 
8.8 (2.4 to 12.2) % 
22.1 (19.6 to 26.8) kg 
21.4 (14.7 to 23.2) % 
From day of surgery to 12 months 
Postoperative 
14.3 (7.0 to 26.8) kg 
10.7 (5.6 to 25.0) % 
9.3 (2.9 to 13.5) kg 
7.3 (2.9 to 9.9) % 
26.3 (19.9 to 29.2) kg 
24.7 (19.5 to 25.9) % 
Weight change from start of MWM to 12 
months after surgery (TWC) 
28.3 (17.2 to 40.1) kg 
17.9 (13.0 to 29.3) % 
18.6 (9.0 to 25.4) kg 
13.8 (6.9 to 17.6) % 
40 (32.3 to 43.8) kg 
29.3 (23.1 to 34.3) % 
 
 
 
 
 
 
Table S3. The relationship between weight change during GLP-1 treatment and weight change from day of surgery till 12 
months postoperative. GLP-1 RA: Glucagon-like peptide-1 receptor agonist; LAGB: Laparoscopic Adjustable Gastric Band; 
RYGB: Roux-en-Y Gastric Bypass; LSG: Laparoscopic Sleeve Gastrectomy 
 r value p-value 
Total Study Population (n=45)   
Correlations between GLP-1 RA induced weight change in 
Kg, and Weight change induced by surgery in Kg 
0.021 0.892 
Correlations between Percentage GLP-1 RA induced weight 
change, and Percentage weight change induced by surgery 
0.028 0.857 
LAGB (n= 26)   
Correlations between GLP-1 RA induced weight change in 
Kg, and Weight change induced by surgery in Kg 
0.024 0.909 
Correlations between Percentage GLP-1 RA induced weight 
change, and Percentage weight change induced by surgery 
-0.086 0.677 
RYGB/LSG (n= 19)   
Correlations between GLP-1 RA induced weight change in 
Kg, and Weight change induced by surgery in Kg 
-0.313 0.193 
Correlations between Percentage GLP-1 RA induced weight 
change, and Percentage weight change induced by surgery 
-0.025 0.92 
 
Table S4. Comparison of percentage weight loss post operatively between patients who lost < 3, 5 and 8% weight on GLP-1 
RA treatment and those who lost ≥ 3, 5, and 8%. A negative value indicates weight gain. Data presented as median (IQR). 
GLP-1 RA: Glucagon-like peptide-1 receptor agonist; LAGB: Laparoscopic Adjustable Gastric Band; RYGB: Roux-en-Y Gastric 
Bypass; LSG: Laparoscopic Sleeve Gastrectomy 
 Weight loss following 
GLP-1 RA(>= 3%) 
Weight maintenance or 
weight gain following 
GLP1 RA (< 3%) 
p-
value 
Total Study Population (n=45) N=30 N=15  
% body weight loss between day of 
surgery and 12 months post 
operatively 
11.9% (6.8 to 24.1) 9.9% (5.1 to 25.3) 0.866 
% body weight loss prior to GLP-1 RA 0.2% (0 to 3.2) 1.8% (0 to 7.5) 0.17 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
21.2% (13.3 to 29.6) 14.6% (6.1 to 29.3) 0.30 
LAGB (n= 26) N=17 N=9  
% body weight loss between day of 
surgery and 12 months post 
operatively 
7.3% (3.4 to 9.4) 6.9% (-2.8 to 10.8) 
 
0.916 
% body weight loss prior to GLP-1 RA 0.0% (-0.7 to 3.1) 4.3% (0.0 to 8.8%) 0.58 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
16.3% (11.7 to 17.9) 7.2% (0.1 to 16.1) 0.15 
RYGB/LSG (n= 19) N=13 N=6  
% body weight loss between day of 
surgery and 12 months post 
operatively 
23.8% (17.3 to 25.7) 25.6% (17.4 to 28.4) 
 
0.521 
% body weight loss prior to GLP-1 RA 0.3% (0 to 4.5) 0.4% (-0.2 to 4.6) 0.90 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
32.9% (24.0 to 37.7) 29.3% (20.7 to 32.9) 0.52 
 >= 5% weight loss <5% weight loss following p-
following GLP-1 RA GLP1 RA value 
Total Study Population (n=45) N=23 N=22  
% body weight loss between day of 
surgery and 12 months post 
operatively 
9.9% (5.0 to 23.6) 15.6% (5.7 to 25.4) 0.4 
% body weight loss prior to GLP-1 RA 0% (0 to 3.4) 12.9% (0 to 5.1) 0.5 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
17.9% (13.0 to 28.2) 20.1% (9.7 to 32.4) 0.9 
LAGB (n= 26) N=15 N=11  
% body weight loss between day of 
surgery and 12 months post 
operatively 
7.3% (3.3 to 9.9) 6.9% (0.4 to 9.9) 
 
0.9 
% body weight loss prior to GLP-1 RA 0 (-0.4 to 3) 4.3% (0 to 7.5) 0.09 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
16.8% (12.8 to 17.9) 10.6% (1.7 to 16.3) 0.134 
RYGB/LSG (n= 19) N=8 N=11  
% body weight loss between day of 
surgery and 12 months post 
operatively 
23.7% (13.7 to 25.4) 25.3% (21.3 to 28.1) 
 
0.3 
% body weight loss prior to GLP-1 RA 1.8% (0 to 6.5) 0.3% (0 to 2.5) 0.4 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
30.9% (23 to 41.2) 29.3% (23.1 to 32.9) 0.6 
 >= 8% weight loss 
following GLP-1 RA 
<8% weight loss following 
GLP1 RA 
p-
value 
Total Study Population (n=45) N=10 N=35  
% body weight loss between day of 
surgery and 12 months post 
operatively 
13.9% (2.9 to 24.9) 10.7% (5.8 to 25.3) 0.8 
% body weight loss prior to GLP-1 RA 0% (-0.1 to 3.6) 4.3% (1.8 to 7.9) 0.6 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
23.1% (16.1 to 41.2) 17.6% (12.8 to 28.5) 0.2 
LAGB (n= 26) N=6 N=20  
% body weight loss between day of 
surgery and 12 months post 
operatively 
5.3% (-1.7 to 11.4) 7.8% (3.9 to 9.9) 
 
0.5 
% body weight loss prior to GLP-1 RA 0% (-0.3 to 1.5) 2% (-0.3 to 4.8) 0.4 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
17.5% (10.6 to 20.5) 13.2% (6.4 to 17.2) 0.2 
RYGB/LSG (n= 19) N=4 N=15  
% body weight loss between day of 
surgery and 12 months post 
operatively 
25.2% (24.1 to 27.6) 23.6% (15.1 to 25.9) 
 
0.4 
% body weight loss prior to GLP-1 RA 1.8% (-0.1 to 9.6) 3.3% (0 to 3.3) 0.7 
% body weight loss between start of 
medical weight management and 12 
months post operatively 
41.2% (35.3 to 42.2) 28.5% (22.8 to 32.9) 0.002 
 Figure 1. A schematic representation of a patient’s journey from the start of Weight Management to 12 months after 
bariatric surgery.  A refers to the Total Weight Change (kg) which is calculated by Weight taken at the Start of Weight 
Management (kg; WMS Baseline Weight) minus weight measured 12 months post-Bariatric Surgery (kg). B refers to Pre- 
GLP-1 RA weight change (kg) as calculated by WMS Baseline Weight minus weight at start of GLP-1 RA treatment. C refers 
to GLP-1RA induced weight change (kg) as calculated by weight measured at the start of GLP-1 RA treatment minus the 
weight measured at the end of GLP-1 RA treatment. D refers to weight change induced by Bariatric surgery (kg) as 
calculated by weight measured pre-operatively minus the weight measured 12 months post-Bariatric Surgery. 
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